Tanja Obradovic: Orum Therapeutics is focusing its innovation pipeline on degrader-antibody conjugates
Tanja Obradovic shared a post on LinkedIn:
“Great news from Orum Therapeutics, a Korea based biotech has been just announced. It is filing for an initial public offering (IPO) on South Korea’s Kosdaq market.
Company is focusing it innovation pipeline on degrader-antibody conjugates (DACs). Orum’s proprietary Dual-precision Targeted Protein Degradation (TPD) approach uses antibodies to deliver small molecule targeted protein degrader payloads to targeted cancer cells. The TPD technology produced two most advanced products.
ORM-5029 (targets HER2) and ORM-6151 (targets CD33 and acquired by BMS). Great news and very interesting potential for the new therapeutic modality. South Korea’s biotech industry is definitively experiencing rapid growth.”
Source: Tanja Obradovic/LinkedIn
Tanja Obradovic is the Vice President of Oncology Scientific Affairs at ICON PLCh. She has over 20 years of clinical research experience and has led major pharmaceutical companies for 13 years. Her research focuses on small molecules, antibodies, cell and gene therapy, and major immunotherapy of PD1 inhibitors.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023